November 20, 2026 · The American journal of medicine · DOI: 10.1016/j.amjmed.2026.11.005

Impact of weight reduction therapies on fibrosis and adverse liver outcomes in metabolic dysfunction-associated liver disease: an evidence-based review.

Listen to this summary

This evidence-based review asks whether weight reduction therapies (lifestyle, bariatric/metabolic surgery, and pharmacotherapies) improve liver fibrosis, noninvasive stiffness measures, and major adverse liver outcomes (MALO) in metabolic dysfunction-associated steatohepatitis (MASH). The authors find that multimodal weight loss is generally associated with fibrosis regression and lower MALO risk, but heterogeneity across studies and limited evidence that weight loss independently drives these benefits temper the conclusions. They recommend continued monitoring of patients with MASH and fibrosis, with MASH-specific pharmacotherapy considered for non-cirrhotic patients with moderate-to-advanced fibrosis (F2-F3), alongside diet and exercise.

Naim Alkhouri, Jaideep Behari, Danielle Zielinski, Eduardo Vilar-Gomez

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play